Zhitong Finance App News, Hengrui Pharmaceutical (01276) issued an announcement. Recently, the company's subsidiary Suzhou Shengdia Biomedical Co., Ltd. received approval from the State Drug Administration (hereinafter referred to as the “State Drug Administration”) to issue a “Drug Clinical Trial Approval Notice” for injectable SHR-8925, which will conduct clinical trials in the near future.

Injectable SHR-8925 is a therapeutic biological product independently developed by the company. It can specifically bind to tumor cell surface antigens to kill tumor cells, and is intended for the treatment of advanced solid tumors. According to inquiries, no drugs with the same target have been approved for marketing at home or abroad. Up to now, the total R&D investment for injectable SHR-8925 related projects is approximately RMB 11.2 million (unaudited).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.